Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis:: Results of a double-blind, placebo-controlled 3-year study

The efficacy of oral clodronate 800 mg daily to reduce vertebral fractures was studied in 593 women with postmenopausal or secondary osteoporosis. The incidence of vertebral fractures was significantly reduced by 46%. The effect was not modified by the underlying cause of osteoporosis or other baseline factors including bone mineral density, QUS, weight, and smoking.